Cancer immunotherapy has transformed oncology by shifting part of the fight against tumors from conventional chemotherapy and radiation toward the patient’s own immune system. Among the most important advances are immune checkpoint inhibitors, which release molecular brakes that restrain T cells, and engineered or expanded T-cell therapies designed to target malignant cells. Yet these treatments remain ineffective for many patients. Some tumors lack the biological signals needed for T-cell recognition, while others create a hostile microenvironment that suppresses immune activity or evolve rapidly enough to escape attack.

T cells are specialized immune cells capable of identifying abnormal proteins displayed on the surface of cancer cells. After recognizing their targets, they form a close contact zone with the tumor cell, known as an immunological synapse, and release toxic molecules that can trigger the cancer cell to die. This process depends on a series of precisely coordinated interactions between the T cell and the tumor. If any part of that process is weakened—whether because the tumor hides its identifying markers, blocks immune signaling or resists cell death—the immune response may fail even when large numbers of T cells are present.

To search for ways to overcome these barriers, Puig-Saus’ laboratory has developed a drug screening platform capable of testing thousands of chemical compounds. Such platforms allow scientists to observe how individual molecules influence interactions between immune cells and cancer cells. Rather than examining only whether a drug kills tumor cells directly, the UCLA team can investigate whether a compound changes the biological relationship between the tumor and the immune system. This distinction is important because many promising immunotherapy-enhancing drugs may not be effective as standalone cancer treatments.

The screening effort has identified two leading candidates with complementary effects. One compound appears to strengthen the physical and functional interaction between T cells and cancer cells. By improving the formation or stability of the cellular contact needed for immune attack, the drug could help T cells deliver their destructive signals more effectively. This type of intervention may be especially valuable in tumors where immune cells reach the cancer but fail to establish a sufficiently strong or sustained response.

The second candidate acts primarily on tumor cells rather than directly modifying T cells. Preliminary findings suggest that it makes cancer cells more vulnerable to destruction by T cells. In technical terms, the drug may alter pathways controlling tumor-cell survival, stress responses or susceptibility to the molecular machinery released by activated immune cells. The compound could therefore increase the “killability” of cancer cells without requiring researchers to permanently reprogram or intensify the immune cells themselves, potentially offering a different route to improving treatment efficacy.

The new grant will support experiments in preclinical melanoma models to determine whether either compound can boost existing immunotherapies. Researchers will evaluate combinations with immune checkpoint inhibitors and T-cell-based treatments, measuring tumor growth, immune-cell activity, treatment durability and possible toxic effects. They will also study how the compounds work at the molecular level, seeking to identify the cellular pathways responsible for improved immune recognition or tumor destruction. Understanding those mechanisms will be essential for selecting appropriate patients and designing safe clinical trials.

Melanoma provides a particularly important testing ground because it can carry a high number of mutations, creating abnormal proteins that immune cells may recognize. Despite this vulnerability, melanoma can still suppress immune responses and develop resistance after an initial treatment benefit. A drug that restores the effectiveness of T cells or exposes a tumor’s hidden weaknesses could help extend responses in patients who do not benefit from current therapies or whose cancers return after treatment. The researchers will need to establish whether the compounds work broadly across genetically different melanomas or only in tumors with particular biological features.

“If successful, these drugs could significantly improve the effectiveness of current immunotherapies and help more patients benefit from these treatments,” Puig-Saus said. She is an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy. Because the compounds are being developed as partners for existing treatments rather than replacements for them, the strategy could potentially be adapted to other cancers in which immune evasion and resistance limit therapeutic success.

The project remains at the preclinical stage, and its compounds have not yet been established as safe or effective treatments for people. Many candidates that show promise in laboratory systems ultimately fail because they produce unexpected toxicity, lose activity in complex tumors or cannot be delivered at useful doses. The UCLA team’s upcoming studies will therefore examine both therapeutic benefit and safety while tracing the precise mechanisms involved. If the candidates continue to perform well, they could provide a foundation for future clinical development and offer a new way to make the immune system’s attack on cancer more precise, persistent and effective.

Subject of Research: Cancer immunotherapy enhancement using drug-based strategies for melanoma and potentially other cancers

Article Title: UCLA Team Receives $3.9 Million Grant to Develop Drugs That Could Strengthen Cancer Immunotherapy

Web References: https://www.uclahealth.org/cancer/members/cristina-puig-saus; https://www.uclahealth.org/cancer

Keywords: Immunotherapy, cancer immunology, immune system, immune response, cancer research, cancer, melanoma, skin cancer, T-cell therapy, immune checkpoint inhibitors

Immunoengineering represents a cutting-edge interdisciplinary domain that utilizes engineering tools to interrogate and modulate the immune system with unprecedented precision. This modulation involves either enhancing immune responses, as needed in cases of cancer or viral infections, or dampening them to treat autoimmune conditions. OCIE’s approach leverages this dual capability, seeking to systematically dissect immune mechanisms and develop innovative treatments tailored to diverse pathological contexts. The center is spearheaded by Wei Chen, Ph.D., an expert in cancer immunotherapy, and Chongle Pan, Ph.D., a leader in data science and computational biology, underscoring the center’s commitment to combining experimental and computational methodologies.

A critical infrastructure component of OCIE is the establishment of two synergistic research cores. The Immunomodulation Technology Core focuses on experimental laboratory work, providing researchers with advanced tools and methodologies to probe immune responses at the molecular and cellular levels. This core facilitates the development of novel immunotherapeutic strategies by enabling manipulation of immune cells and pathways in controlled laboratory settings. Complementing this, the Omics Data Science Core brings to bear state-of-the-art computational techniques and bioinformatics expertise. This core is dedicated to designing experiments, managing large-scale omics datasets, and applying machine learning algorithms to derive predictive models from complex immune system data.

The importance of integrating high-dimensional omics data with immunological experimentation arises from the sheer volume and complexity of information generated by modern biomedical research. Immunoengineering studies produce vast arrays of data spanning genomics, transcriptomics, proteomics, and metabolomics, which require sophisticated analytics to unravel the underlying biological insights. Through the synergy of experimental and computational cores, OCIE aims to build predictive frameworks that can forecast immune behavior under various therapeutic interventions, a critical step toward personalized medicine.

Dr. Wei Chen, leading the center, emphasizes the transformative potential of this integrated platform. Chen highlights his personal research in immunotherapy for late-stage cancer patients where the amalgamation of immunological insights with omics-driven data analysis has yielded innovative therapeutic avenues. OCIE aspires not only to be a hub of scientific innovation but also to serve as a collaborative platform for researchers across Oklahoma, fostering an ecosystem where discoveries rapidly translate into clinical applications that improve patient outcomes. This endeavor is positioned as a pioneering center nationally, with no existing comparable entity focusing on the convergence of immunomodulation and omics data science.

The Omics Data Science Core, under Chongle Pan’s guidance, is focused on harnessing artificial intelligence (AI), predictive modeling, and machine learning to provide actionable intelligence from immune system datasets. Because immune responses are highly dynamic and context-dependent, understanding them requires more than descriptive analysis—it requires predictive models that can simulate immune responses and predict therapeutic success. Pan’s work aims to democratize access to these computational tools, enabling researchers statewide to maximize the scientific yield of their immune-related studies.

OCIE also prioritizes the development of future scientific leaders by selecting and mentoring early-career investigators. Four junior faculty members have been appointed as research project leaders, each matched with experienced mentors from OU’s Norman and Health Sciences campuses. These young scientists spearhead innovative projects encompassing a broad range of immunoengineering challenges—from bat immunology related to coronavirus infection to sophisticated neuroimaging-guided immunotherapy in brain cancer, to computational and molecular investigations aimed at novel cancer vaccine design and understanding rare sarcoma immune microenvironments.

One project, led by Dr. Daniel Becker, explores the immune response of migratory bats to coronavirus infections, potentially offering vital clues to host-pathogen dynamics and natural viral resistance mechanisms. Dr. David Miller’s research focuses on glioblastoma, employing neuroimaging to guide immunotherapy approaches for one of the most aggressive and lethal brain tumors. Marmar Moussa’s work delves into T-cell receptor and antigen interactions, a fundamental aspect of developing effective peptide-based cancer vaccines. Meanwhile, Dr. Abdul Rafeh Naqash studies alveolar soft part sarcoma’s tumor immune microenvironment, identifying molecular vulnerabilities that could be therapeutically targeted.

Beyond project-specific research, OCIE fosters a vibrant scientific community through monthly seminars, interactive research roundtables, hands-on training workshops, and an annual symposium designed to catalyze interdisciplinary collaboration. A core mission of the center is to fund pilot research and promote team science, connecting basic immunologists, translational scientists, and clinicians to accelerate the journey from bench to bedside. This integrative approach aims to dismantle traditional silos and facilitate comprehensive understanding and manipulation of immune responses in multiple disease contexts.

The establishment of OCIE arrives at a strategic moment, given Oklahoma’s inclusion among the states benefiting from the NIH Institutional Development Award (IDeA) program. This program aims to enhance the research infrastructure in states that historically have received lower levels of NIH funding, thereby expanding national biomedical research capacity and equity. Through OCIE, Oklahoma becomes a vanguard for immunoengineering, reinforcing its scientific stature and capacity for biomedical innovation.

OCIE’s vision is nothing short of revolutionary. By converging immunology, engineering, and data science, the center establishes a model for precision immunomodulation. With capabilities spanning experimental manipulation and bioinformatic modeling, OCIE situates itself at the frontier of modern biomedicine, promising breakthroughs that could redefine immune system-based therapies. The center epitomizes the future of interdisciplinary biomedical research—where computation and experimentation coalesce to decode the immune system’s complexities and unlock new therapeutic vistas.

In summary, the University of Oklahoma’s Oklahoma Center for ImmunoEngineering leverages substantial NIH investment to create an unprecedented platform that integrates experimental immunomodulation technologies with advanced omics data science. Co-led by Drs. Wei Chen and Chongle Pan, OCIE is poised to make transformative advances in understanding and controlling immune function over diverse diseases such as cancer, viral infections, and autoimmune disorders. By supporting a new generation of interdisciplinary scientists and fostering collaboration, OCIE heralds a new era in immunoengineering, setting the stage for discoveries that hold the promise of vastly improved human health outcomes.

Subject of Research: Immunoengineering, Immunomodulation, Omics Data Science, Immunotherapy, Computational Biology

Article Title: University of Oklahoma Launches Pioneering Oklahoma Center for ImmunoEngineering with $11.5M NIH Award

News Publication Date: Not specified (most recent based on funding announcement)

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/f8d658b4-8a4c-4e7e-b61d-c04c29ac2b93/Rendition/low-res/Content/Public

Image Credits: Jonathan Kyncl/University of Oklahoma

Keywords: Immunoengineering, Immunomodulation, Immune Regulation, Omics Data Science, Artificial Intelligence, Cancer Immunotherapy, Predictive Modelling, Machine Learning, Immune System, Biomedical Engineering, Systems Biology

Developed through a collaborative effort between the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and teams at the University of California, San Francisco as well as the Helen Diller Family Comprehensive Cancer Center, CIPHER-seq represents a significant step forward in immune profiling. Unlike traditional approaches that primarily focus on RNA sequencing, which captures the “blueprint” of cellular activity, this method integrates multiple layers of biological information by also quantifying proteins both on and within the cell. This layered analysis provides a clearer, more dependable window into cellular function, tracing the direct molecular players responsible for immune responses, including cytokines, the potent signaling proteins critical to immune communication and regulation.

Single-cell RNA sequencing has vastly expanded the horizon of biomedical research by allowing high-throughput characterization of gene expression across thousands of individual cells. However, RNA transcripts alone can provide an incomplete and sometimes misleading portrayal of cellular states, as they represent instructions that do not always correlate with final protein output. This discrepancy is especially pronounced for cytokines—key mediators that dictate immune cell behavior, guide inflammatory responses, and influence tumor dynamics. RNA levels fluctuate rapidly and are transient, while proteins accumulate more slowly and persist longer, creating a temporal disconnect that RNA sequencing alone cannot resolve. Hence, understanding immune responses necessitates an integrative approach combining both RNA and protein data to capture the full biological narrative.

CIPHER-seq addresses this complexity by gently preserving immune cells during processing, thus minimizing artificial stress responses that have confounded earlier methods. Standard preparation techniques can induce mitochondrial stress and other cellular perturbations, thereby polluting data with artifacts that mask authentic biological signals. The gentle preservation employed in CIPHER-seq maintains cells closer to their natural physiological state, ensuring that measurements reflect true cellular function rather than experimental distortion. This refinement is crucial for accurately mapping the nuanced processes by which immune cells activate, communicate, and regulate their environments, especially within the challenging context of cancer and inflammation.

Technically, CIPHER-seq captures a comprehensive immunological snapshot from a single cell by simultaneously profiling the entire transcriptome along with intracellular and surface protein markers, including the cytokines sequestered within cells before secretion. The methodology integrates advanced sequencing protocols with protein detection reagents, enabling the simultaneous measurement of thousands of RNA molecules alongside the phenotypic markers and signaling proteins that define the cell’s current status. This multimodal profiling unveils the precise molecular choreography that governs immune activity, facilitating a detailed reconstruction of how cells respond to stimuli and enact immune functions at the molecular level.

To validate the capabilities of this platform, researchers conducted activation assays whereby immune cells were stimulated and tracked over time. CIPHER-seq successfully detected dynamic increases in the production of critical cytokines such as interferon-gamma and tumor necrosis factor—both central players in modulating immune defense and tumor suppression. Through sophisticated computational algorithms that arrange cells along temporal trajectories of activation, the study observed that RNA levels surged first as cells “planned” their response, followed by a subsequent, modestly delayed rise in protein expression, representing the “execution” phase of immune activity. This sequential timing underscores the value of analyzing both RNA and protein simultaneously to unravel the true dynamics of immune responses.

The ability to monitor cytokines at both the transcriptional and protein levels enhances the granularity with which scientists can understand the mechanisms by which immune cells decide to attack cancer cells, ignore them, or paradoxically support tumor growth through chronic inflammation or immune suppression. By moving beyond static single-layer snapshots to continuous, multimodal timelines, CIPHER-seq empowers researchers to uncover hidden regulatory steps, identify novel biomarkers, and elucidate resistance pathways that have heretofore remained obscured in cancer immunology. These insights have far-reaching implications for advancing immunotherapy—tailoring treatments that are not only more effective but also personalized to a patient’s unique immune landscape.

Justin Taylor, M.D., Sylvester physician-scientist and co-senior author of the study, emphasizes that proteins reveal the actual functional endpoints of immune signaling that RNA alone cannot specify. “RNA gives us clues about where a cell is headed,” Dr. Taylor explains, “but proteins show us where it actually arrives. This clearer picture could significantly refine how immunotherapies are designed and how clinicians anticipate treatment outcomes.” This transformative perspective reconceptualizes immunology research, prioritizing integrated molecular datasets that mirror biological reality rather than relying on partial, indirect proxies of cellular activity.

The implications of CIPHER-seq extend beyond cancer to other immune-mediated diseases characterized by aberrant cytokine activity and immune dysfunction. Chronic inflammatory disorders, autoimmune diseases, and infections could all benefit from this technology’s ability to decode immune cell behavior with greater accuracy and precision. By providing a robust, low-artifact platform that delineates the timing and magnitude of cytokine production and signaling events across heterogeneous immune cell populations, scientists can develop targeted therapeutic strategies that modulate immune responses more effectively and safely.

Moreover, the computational framework accompanying CIPHER-seq analysis leverages advanced bioinformatics to correlate complex data streams from RNA and protein channels, mapping immune cell populations onto activation trajectories and functional states with remarkable resolution. This approach empowers researchers to dissect intercellular heterogeneity, pinpoint subtle regulatory nodes, and predict cellular fates in response to tumor microenvironments or therapeutic interventions. The fusion of experimental and computational innovations embodied by CIPHER-seq marks a milestone for systems immunology, setting new standards for accuracy and depth in single-cell profiling technologies.

Looking ahead, integration of CIPHER-seq with other emerging single-cell technologies, such as spatial transcriptomics and epigenetic profiling, could further enhance our ability to chart immune responses in situ within tissue architectures. Such multimodal profiling at unprecedented scales holds the promise to unveil the spatial and temporal regulatory networks that drive immune evasion, inflammation resolution, and therapeutic resistance. As researchers continue to refine and expand this technology, CIPHER-seq is poised to become an indispensable tool in the arsenal for cancer immunotherapy research and beyond, bridging fundamental biology and clinical application in the quest to decipher and harness the immune system.

In summary, the advent of CIPHER-seq constitutes a transformative advance in single-cell immunology by capturing the dual biochemical narratives of RNA and protein within the same immune cells. This multimodal platform transcends the limitations of prior methodologies by reducing artificial cell stress and revealing the precise sequence of cytokine gene and protein expression during immune activation. Providing an integrative and dynamic portrait of immune cell behavior, CIPHER-seq lays the groundwork for improved immunotherapeutic strategies and more accurate clinical predictions in cancer and other immune-related diseases. The study’s publication in the April 8, 2026 issue of Scientific Reports signals a new era in combining molecular granularity with temporal resolution, fostering a deeper understanding of how immune responses genuinely unfold one cell at a time.

Subject of Research: Immune cell behavior and cytokine signaling profiling using multimodal single-cell sequencing technology

Article Title: CIPHER-seq enables intracellular multimodal profiling of cytokine responses in single immune cells

News Publication Date: April 8, 2026

Web References:
http://dx.doi.org/10.1038/s41598-026-44946-y

Image Credits: Photo by Sylvester Cancer

Keywords: Cancer immunotherapy, Cytokines, Cancer genomics, Genome sequencing, RNA sequencing, Single cell sequencing, Immune cells, Cancer immunology, Immunotherapy

Ovarian cancer has long been recognized for its aggressive nature and poor prognosis, often due to late-stage diagnosis and a complex tumor microenvironment that can evade immune detection. Understanding the underlying mechanisms that facilitate this evasion is critical for the development of more effective therapies. The research conducted by He and colleagues provides compelling evidence that SOAT1 is not merely a bystander in ovarian cancer cells but plays an active role in modulating the immune landscape.

One of the fundamental aspects of the immune response in cancer is the activity of CD8+ T cells, which are cytotoxic lymphocytes tasked with identifying and destroying malignant cells. However, their effectiveness can be significantly hindered by signals from the tumor microenvironment. The authors hypothesize that SOAT1 influences lipid metabolism in ovarian cancer cells, thereby altering how these cells interact with CD8+ T cells. Their findings suggest that targeting SOAT1 may enhance the activity of these immune cells, providing a potential therapeutic avenue to reinvigorate anti-tumor immunity.

The study utilizes a range of experimental methodologies, including in vitro cell culture systems and in vivo mouse models, to dissect the role of SOAT1. By manipulating SOAT1 expression in ovarian cancer cell lines, the team was able to demonstrate distinct effects on CD8+ T cell activation and proliferation. The results indicate that SOAT1 regulates lipid composition within the tumor, which subsequently influences the expression of immunomodulatory molecules, further affecting the tumor-immune interaction.

The research is particularly timely; there has been a surge in interest surrounding metabolic pathways in cancer. While studies commonly focus on glycolysis and oxidative phosphorylation, the implications of lipid metabolism are often overlooked. This study emphasizes the need to broaden our understanding of cancer metabolism by including lipid metabolic enzymes like SOAT1. The findings contribute to a more nuanced picture of how cancer cells rewire metabolic pathways to not only support their own survival but also to manipulate immune responses.

In addition to providing evidence for the role of SOAT1 in ovarian cancer, this research raises important questions about the broader impact of lipid metabolism on tumor immunology. For instance, could modulation of lipid pathways represent a novel strategy to boost the efficacy of immunotherapies? The potential for combining targeted therapies with immunotherapeutic approaches is enormous, and understanding the interplay between these modalities is essential.

Beyond the laboratory insights, the implications of this research could reverberate throughout clinical practice. The identification of SOAT1 as a critical regulator of immune response could lead to the development of novel biomarkers for ovarian cancer patients, aiding in predictions of treatment responses and outcomes. More importantly, targeting SOAT1 in conjunction with existing therapies may enhance the overall efficacy, potentially leading to improved survival rates for patients battling this notorious disease.

While the journey from bench to bedside is fraught with challenges, the findings presented in this study underscore a vital step forward. The collaborative efforts of researchers across disciplines are crucial for translating these discoveries into therapeutic interventions. A multidisciplinary approach, integrating insights from molecular biology, immunology, and pharmacology, is essential for devising novel strategies that can effectively target the unique metabolic landscapes of tumors.

The study also sparks discussions about the potential for combination therapies that target both cancer metabolism and the immune system simultaneously. Such strategies could be particularly effective for tumors like ovarian cancer that exhibit substantial heterogeneity. Furthermore, ongoing clinical trials could offer insights into how modulation of lipid metabolism may enhance the outcomes of existing immunotherapies, driving forward the next generation of cancer treatments.

As the landscape of cancer therapy evolves, the integration of findings such as those from He et al. into clinical settings becomes increasingly relevant. The prospect of developing targeted therapies against SOAT1 not only opens new avenues for research but may also offer hope for patients facing challenging diagnoses. Ultimately, understanding the intricate networks that govern tumor immunity remains a promising frontier in cancer research.

In conclusion, the research on SOAT1’s role in mediating immune responses within ovarian cancer cells stands as a beacon of innovation in oncology. By uncovering the connections between lipid metabolism and immune modulation, this study paves the way for future explorations into therapeutic strategies that could refine how we combat ovarian and potentially other cancers. As science progresses, the hope remains that such discoveries will translate into actionable insights capable of improving patient outcomes and enriching the arsenal against cancer.

Subject of Research: The role of SOAT1 in ovarian cancer cell lipid metabolism and its influence on immune response mediated by CD8+ T cells.

Article Title: SOAT1 in ovarian cancer cells regulates immune response mediated by CD8+ T cells.

Article References:

He, J., Siu, M.K., Long, R. et al. SOAT1 in ovarian cancer cells regulates immune response mediated by CD8⁺ T cells.
J Ovarian Res 18, 273 (2025). https://doi.org/10.1186/s13048-025-01832-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01832-x

Keywords: SOAT1, ovarian cancer, CD8+ T cells, immune response, lipid metabolism, cancer immunotherapy, tumor microenvironment.

TAMs and MDSCs derive primarily from circulating monocytes and bone marrow progenitors, yet recent evidence highlights the contribution of extramedullary hematopoiesis, especially from splenic hematopoietic stem and progenitor cells (HSPCs), to the continuous replenishment of these populations within tumors. This systemic mobilization is driven by tumor-secreted factors that induce emergency myelopoiesis, skewing progenitor differentiation toward immunosuppressive myeloid phenotypes. Once recruited, these cells colonize the tumor stroma, where chemokines such as CCL2, CXCL8, and colony-stimulating factor 1 (CSF-1) orchestrate their accumulation, survival, and proliferation through engagement of receptors like CCR2, CXCR2, and CSF-1R.

The metabolic landscape within the TME imposes significant constraints, including hypoxia and nutrient scarcity, compelling myeloid cells to undergo extensive metabolic reprogramming to sustain their functions. TAMs often upregulate glycolytic pathways, with lactate produced via enhanced glycolysis functioning as an immunomodulatory metabolite that stabilizes hypoxia-inducible factor 1-alpha (HIF-1α). This stabilization promotes epigenetic reprogramming through histone lactylation, driving the transcription of immunosuppressive genes such as interleukin-10 (IL-10) and arginase-1 (Arg1). Concurrently, shifts toward fatty acid oxidation (FAO) and amino acid metabolism are prevalent, with lipid accumulation in TAMs inducing chemokine secretion (e.g., CCL20) that attracts regulatory T cells (Tregs), further reinforcing immune evasion.

MDSCs exploit amino acid metabolism, particularly through the catabolism of arginine and tryptophan, to impair effector T cell function. Enzymes such as arginase and indoleamine 2,3-dioxygenase (IDO) contribute to the depletion of these critical nutrients, thus blunting anti-tumor immune responses. Moreover, MDSCs themselves rely heavily on glutamine and FAO pathways for energy and survival, processes intricately regulated by tumor-derived exosomes and cytokines, creating a feedback loop that perpetuates their suppressive capacity. The nuanced interplay between cellular metabolism and immunosuppressive signaling underscores metabolic reprogramming as a central axis dictating myeloid cell function in cancer.

Intracellular signaling cascades governing myeloid cell biology in the TME include activation of transcription factors such as signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). These pathways are potentiated under hypoxic and metabolic stress conditions, augmenting myeloid survival and facilitating a phenotype conducive to tumor promotion. Additionally, autophagy modulates the cellular homeostasis and plasticity of TAMs and MDSCs, supporting their adaptation to hostile microenvironmental niches. The integration of these diverse signals ensures the persistence and expansion of myeloid populations that subvert immune surveillance.

Therapeutic efforts to mitigate the pro-tumoral impact of myeloid cells have intensified, focusing on strategies to disrupt recruitment, survival, and metabolic dependencies. Clinical trials investigating CSF-1R inhibitors aim to curtail TAM infiltration, while CCR2 and CXCR2 blockade targets monocyte and MDSC chemotaxis. Metabolic interventions targeting rate-limiting enzymes, such as 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in glycolysis and carnitine palmitoyltransferase 1A (CPT1A) in FAO, hold promise in reprogramming myeloid phenotypes toward less suppressive states. Concurrent inhibition of arginase and IDO attempts to preserve amino acid availability for effector lymphocytes. However, the clinical translation of such approaches is challenged by compensatory immune mechanisms including polymorphonuclear MDSC infiltration and Treg expansion, highlighting the need for combinatorial and precision therapies.

Advancements in single-cell transcriptomics and spatial proteomics have revolutionized the dissection of myeloid heterogeneity within the TME. Distinct subsets—the likes of TREM2-positive TAMs and PD-L1-expressing macrophages—demonstrate divergent functional roles influenced by tumor type, tissue localization, and metabolic milieu. Unexpectedly, PD-L1+ macrophages have been associated with improved patient prognosis in hepatocellular carcinoma, challenging their traditional categorization as solely immunosuppressive. Similarly, lipid-associated macrophage subsets identified in aggressive triple-negative breast cancer have been implicated in resistance to immune checkpoint blockade, underscoring the heterogeneity and adaptability of these cells.

Explorations into the interplay between myeloid cells and other immune and stromal constituents reveal complex ecosystems driving tumor fate. Interactions with cancer-associated fibroblasts, neutrophils, and B cells create networks that can either facilitate or restrain tumor progression. The conceptual framework of “onco-spheres” envisions tumors as multipartite ecosystems with intricate crosstalk between local and systemic immunity, suggesting that therapeutic success depends on addressing these multifactorial interactions. Modulation of cholesterol metabolism and epigenetic regulators represents emergent avenues to recalibrate myeloid function, potentially enhancing immune responsiveness.

Beyond conventional therapeutic pipelines, repurposing existing drugs such as statins and glutamine antagonists to target metabolic vulnerabilities in myeloid cells offers an exciting translational prospect. β-glucan-like agents that “train” innate immunity indicate a novel paradigm, wherein myeloid cells are reeducated to mount enhanced anti-tumor responses. Such approaches underscore a shift from mere depletion to functional reprogramming of the myeloid compartment, aiming to restore immune equilibrium within the TME.

Addressing therapeutic resistance will require integrated strategies that simultaneously dismantle myeloid cell-mediated immune evasion and potentiate T cell efficacy. This necessitates an expanded focus on transcriptional and metabolic networks that govern cellular plasticity and intercellular signaling. Employing multi-omics integration alongside functional validation will be pivotal in identifying actionable targets that discriminate between pro- and anti-tumor myeloid subsets. Precision immunomodulation may ultimately transform the therapeutic landscape by turning once-pro-cancer myeloid cells into potent allies against malignancy.

The rapidly evolving understanding of myeloid cell biology in oncology heralds a new era of immunotherapy. By unraveling the complex metabolic and signaling circuits underpinning their diverse phenotypes, researchers can systematically exploit these vulnerabilities to reverse immune suppression, inhibit metastasis, and enhance durable responses. The convergence of experimental and computational methodologies promises to deliver personalized interventions that modulate the TME with unprecedented precision, marking myeloid cells not as mere bystanders but as linchpins in the fight against cancer.

Subject of Research: Not applicable
Article Title: Myeloid cells: key players in tumor microenvironments
News Publication Date: 5-Mar-2025
Web References: http://dx.doi.org/10.1007/s11684-025-1124-8
Image Credits: Qiaomin Hua, Zhixiong Li, Yulan Weng, Yan Wu, Limin Zheng
Keywords: Health and medicine